Sumitomo Pharma Yönetim

Yönetim kriter kontrolleri 2/4

Sumitomo Pharma CEO'su Toru Kimura, Jan2016 tarihinde atandı, in görev süresi 8.83 yıldır. şirketin hisselerinin 0.02% doğrudan sahiptir ve bu hisselerin değeri ¥ 48.04M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.2 yıl ve 3.9 yıldır.

Anahtar bilgiler

Toru Kimura

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	8.8yrs
CEO sahipliği	0.02%
Yönetim ortalama görev süresi	2.2yrs
Yönetim Kurulu ortalama görev süresi	3.9yrs

Son yönetim güncellemeleri

Recent updates

Sumitomo Pharma (TSE:4506) Has Debt But No Earnings; Should You Worry?

Nov 25

Is There An Opportunity With Sumitomo Pharma Co., Ltd.'s (TSE:4506) 38% Undervaluation?

Sep 12

There's No Escaping Sumitomo Pharma Co., Ltd.'s (TSE:4506) Muted Revenues Despite A 26% Share Price Rise

Aug 16

A Piece Of The Puzzle Missing From Sumitomo Pharma Co., Ltd.'s (TSE:4506) 28% Share Price Climb

Jun 26

Is Sumitomo Pharma Co., Ltd. (TSE:4506) Trading At A 34% Discount?

May 13

Market Cool On Sumitomo Pharma Co., Ltd.'s (TSE:4506) Revenues

Apr 17

CEO

Toru Kimura (64 yo)

8.8yrs

Görev süresi

Mr. Toru Kimura, Ph D., is Representative Director, President & CEO of Sumitomo Pharma Co. Ltd. from June 25, 2024.Mr. Toru serves as Director at Sumitomo Pharma America, Inc. since 2024. He served as Rep...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Toru Kimura	Representative Director	8.8yrs	Veri yok	0.020% ¥ 48.0m
Motoyuki Sakai	Representative Director and Executive VP of Corporate Planning	less than a year	Veri yok	Veri yok
Hiroyuki Baba	Mngg Exec. Officer of Global Data Design	7.6yrs	Veri yok	0.0015% ¥ 3.7m
Naoki Noguchi	Executive Officer of Corporate Governance & Communications	2.6yrs	Veri yok	Veri yok
Yoshiharu Ikeda	Managing Executive Officer of Drug Research Division	4.4yrs	Veri yok	0.0038% ¥ 9.3m
Koichi Kozuki	E.O. of R. Aff.	1.8yrs	Veri yok	Veri yok
Shigeyuki Nishinaka	Managing Executive Office	7.6yrs	Veri yok	0.0020% ¥ 4.9m
Isao Shimizu	Executive Officer	1.8yrs	Veri yok	Veri yok
Kenji Ueno	Executive Officer	1.8yrs	Veri yok	Veri yok
Hideyuki Harada	Managing Exe. Officer of Tech. R&D Div.	3.6yrs	Veri yok	Veri yok
Tsutomu Nakagawa	Executive Officer	1.8yrs	Veri yok	0.00076% ¥ 1.9m
Yumi Sato	Exe Off of Drug Dev Div	1.8yrs	Veri yok	Veri yok

2.2yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim: 4506 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Toru Kimura	Representative Director	8.4yrs	Veri yok	0.020% ¥ 48.0m
Motoyuki Sakai	Representative Director and Executive VP of Corporate Planning	less than a year	Veri yok	Veri yok
Yoshiharu Ikeda	Managing Executive Officer of Drug Research Division	4.4yrs	Veri yok	0.0038% ¥ 9.3m
Tsutomu Nakagawa	Executive Officer	less than a year	Veri yok	0.00076% ¥ 1.9m
Saeko Arai	Independent Outside Director	6.4yrs	Veri yok	Veri yok
Minoru Usui	Independent Outside Director	3.4yrs	Veri yok	Veri yok
Nobuhiro Endo	Independent Outside Director	5.4yrs	Veri yok	Veri yok
Hiroshi Niinuma	Director	less than a year	Veri yok	Veri yok
Takashi Kutsunai	Full-Time Audit & Supervisory Board Member	6.4yrs	Veri yok	0.0065% ¥ 16.0m
Yoshio Iteya	Outside Audit & Supervisory Board Member	6.4yrs	Veri yok	Veri yok
Hisayoshi Kashima	Full-Time Audit & Supervisory Board Member	1.4yrs	Veri yok	0.0035% ¥ 8.6m
Koji Fujimoto	Independent Outside Director	2.4yrs	Veri yok	Veri yok

3.9yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 4506 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.9 yıldır).

Sumitomo Pharma Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Less than half of directors are independent

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 25, 2024

Sumitomo Pharma Co., Ltd. Announces Executive Changes

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 27, 2023

Less than half of directors are independent

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 23, 2022

Recent updates

Sumitomo Pharma (TSE:4506) Has Debt But No Earnings; Should You Worry?

Sumitomo Pharma Co., Ltd. to Report Q3, 2025 Results on Jan 31, 2025

New major risk - Share price stability

Second quarter 2025 earnings: EPS misses analyst expectations

Consensus EPS estimates upgraded to JP¥25.34 loss

Sumitomo Pharma Co., Ltd.(TSE:4506) dropped from FTSE All-World Index (USD)

Is There An Opportunity With Sumitomo Pharma Co., Ltd.'s (TSE:4506) 38% Undervaluation?

There's No Escaping Sumitomo Pharma Co., Ltd.'s (TSE:4506) Muted Revenues Despite A 26% Share Price Rise

Consensus EPS estimates upgraded to JP¥39.20 loss

Price target increased by 14% to JP¥365

Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG for the Treatment of Type 2 Diabetes in Japan

Less than half of directors are independent

Sumitomo Pharma Co., Ltd. to Report Q2, 2025 Results on Oct 30, 2024

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates upgraded to JP¥48.57 loss

A Piece Of The Puzzle Missing From Sumitomo Pharma Co., Ltd.'s (TSE:4506) 28% Share Price Climb

Consensus EPS estimates upgraded to JP¥77.85 loss

Consensus EPS estimates upgraded to JP¥103 loss

Sumitomo Pharma Co., Ltd. to Report Q1, 2025 Results on Jul 31, 2024

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 25, 2024

Full year 2024 earnings: EPS misses analyst expectations

Is Sumitomo Pharma Co., Ltd. (TSE:4506) Trading At A 34% Discount?

Price target decreased by 18% to JP¥334

Consensus EPS estimates fall by 21%

Market Cool On Sumitomo Pharma Co., Ltd.'s (TSE:4506) Revenues

Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2024 Results on May 14, 2024

Price target decreased by 10% to JP¥413

Consensus EPS estimates fall by 24%

Consensus EPS estimates fall by 24%

Consensus EPS estimates fall by 24%

Price target decreased by 7.8% to JP¥442

Consensus EPS estimates fall by 23%

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

New major risk - Share price stability

Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

Sumitomo Pharma Co., Ltd. to Report Q3, 2024 Results on Jan 31, 2024

European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of Endometriosis

Gedeon Richter Plc., Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH Receives European Commission grant for Commercialisation of RYEQO®

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024

Price target decreased by 9.3% to JP¥510

Sumitomo Pharma Announces Positive Topline Results from Phase 3 Clinical Studies Evaluating Vibegron in Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia

Consensus EPS estimates fall by 10%

Consensus EPS estimates fall by 15%

Price target decreased by 11% to JP¥630

Sumitomo Pharma Co., Ltd. to Report Q2, 2024 Results on Oct 31, 2023

Sumitomo Pharma Co., Ltd. (TSE:4506) acquired Assets and rights related lefamulin in China, Hong Kong, Macau and Taiwan from Nabriva Therapeutics plc (OTCPK:NBRV.F), Nabriva Therapeutics US, Inc, Nabriva Therapeutics GmbH and Nabriva Therapeutics Ireland Dac for $15 million.

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

Sumitomo Pharma and Otsuka Announce Topline Results from Phase 3 Diamond 1 and Diamond 2 Clinical Studies Evaluating Ulotaront in Schizophrenia

Consensus EPS estimates fall by 14%

Sumitomo Pharma Co., Ltd. Announces Executive Changes

Sumitomo Pharma Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023

Revolka Ltd. Announces Milestone Achievement in the Collaborative Research with Sumitomo Pharma Co., Ltd

HEALIOS K.K. and Sumitomo Pharma Co. Ltd. Announces Start of Phase 1/2 Study in RPE Tear Using RPE Cells Derived from Allogeneic iPS Cells (HLCR011)

Sumitomo Pharma Oncology, Inc. Presents Updated Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients with Myelofibrosis at European Hematology Association 2023 Hybrid Congress

Consensus EPS estimates fall by 17%

Price target decreased by 10% to JP¥811

Price target decreased by 7.2% to JP¥883

Consensus EPS estimates fall by 26%, revenue upgraded

Sumitomo Pharma Co., Ltd. Announces Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023

Full year 2023 earnings: EPS misses analyst expectations

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 27, 2023

Consensus EPS estimates upgraded to JP¥35.42 loss

Consensus EPS estimates upgraded to JP¥35.42 loss

Upcoming dividend of JP¥7.00 per share at 3.5% yield

Consensus estimates of losses per share improve by 85%

Consensus EPS estimates have been downgraded.

Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2023 Results on May 15, 2023